Fast-acting patented technology helps manage symptoms
Irritable Bowel Syndrome (IBS) is a condition that affects more than five million Canadians. While the pain of this condition can have significant health impacts, there are natural remedies that can help to alleviate these.
IBS is a common chronic gastrointestinal disorder that involves problems with motility (how the bowel moves contents through our intestines) and sensitivity (how the brain interprets sensations in the bowel).
Those affected by IBS may experience recurrent abdominal pain and irregular bowel patterns that are often painful. Symptoms are often chronic and intermittent and may last for months or years*. The first of its kind in Canada, IBgard® is a non-prescription product that uses an innovative targeted technology to deliver peppermint oil directly to the small intestine, where IBS sufferers need it most.
“With more than 120,000 Canadians developing IBS each year, this is a therapeutic area that requires more treatment options,” said Dr. Albert Cohen, Director of Gastroenterology at Sir Mortimer B. Davis Jewish General Hospital in Montreal. “IBgard® presents my current and future patients with more treatment options to combat the distressing symptoms that IBS sufferers live with, such as severe abdominal pain, bloating, diarrhea and constipation.”
IBgard® capsules contain individually triple-coated, sustained-release microspheres of Ultramen®, an ultra-purified peppermint oil. Peppermint oil and its principal component l-Menthol has a history of effectiveness in IBS. However, until now, its targeted delivery to the lower gut has posed a challenge. Only IBgard® utilizes the breakthrough science of SST® (Site Specific Targeting) technology, to deliver microspheres of peppermint oil (in a solid state) to the lower gut.
IBgard® has been shown to start working in as early as 24 hours and provides effective relief of the following symptoms associated with IBS:
- Abdominal pain and discomfort
- Abdominal bloating and distension
- Urgency of bowel movement
The annual economic and national healthcare burden of IBS is in excess of $6.5 billion, not including over-the-counter drugs and prescriptions.
Current acute care inpatient costs for IBS are ranked as Canada’s fourth most expensive digestive disease. In addition, a patient with unmanaged IBS misses an average of 13 work days a year, resulting in an indirect cost of $8 billion in productivity loss a year.
IBgard® is available in the digestive aisle in pharmacies nationwide.
For more information, visit www.IBgard.ca or to learn more about the company, visit www.imhealthscience.com.
- *Canadian Digestive Health Foundation
